2024
Autoimmune Diseases and Risk of Non‐Hodgkin Lymphoma: A Mendelian Randomisation Study
Shi X, Wallach J, Ma X, Rogne T. Autoimmune Diseases and Risk of Non‐Hodgkin Lymphoma: A Mendelian Randomisation Study. Cancer Medicine 2024, 13: e70327. PMID: 39506244, PMCID: PMC11540836, DOI: 10.1002/cam4.70327.Peer-Reviewed Original ResearchConceptsRisk of non-Hodgkin lymphomaNon-Hodgkin's lymphomaAutoimmune diseasesMendelian randomisationType 1 diabetesAssociated with risk of non-Hodgkin lymphomaWeak instrument biasNon-Hodgkin lymphoma subtypesTwo-sample MRNon-Hodgkin lymphoma riskRisk factorsSusceptibility to type 1 diabetesMendelian randomisation studiesCohorts of European ancestryAssociated with riskNo significant associationPotential pleiotropyPotential risk factorsUK BiobankFinnGen studyNon-HodgkinHaematological malignanciesRandomised studyEuropean ancestrySignificant association
2021
Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study
Dwyer KE, Wang R, Cozen W, Cartmel B, Wiemels JL, Morimoto LM, Metayer C, Ma X. Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: cebp.0535.2021. PMID: 34548330, DOI: 10.1158/1055-9965.epi-21-0535.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaT-cell non-Hodgkin lymphomaCase-control studyBirth characteristicsMode of deliveryYear of birthOdds ratioNHL riskUnconditional multivariable logistic regression modelsPopulation-based case-control studyCases of NHLMultivariable logistic regression modelConfidence intervalsAge of diagnosisPediatric Burkitt lymphomaLogistic regression modelsCesarean sectionHistologic subtypeDecreased riskHodgkin's lymphomaMaternal ageBurkitt's lymphomaElevated riskLower riskMaternal education
2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansLymphoma, Non-HodgkinMaleRituximabTreatment OutcomeConceptsRituximab discontinuationRituximab initiationHodgkin's lymphomaRelative riskPhysician experienceHigh-quality cancer careOlder adultsInitiation of rituximabEarly treatment discontinuationInfusion-related reactionsPopulation-based studySEER-Medicare dataNon-Hodgkin lymphomaModified Poisson regressionCancer treatment outcomesEarly discontinuationTreatment discontinuationAnticancer immunotherapyPhysician volumeCancer careImproved outcomesOncologists' experiencesTreatment outcomesDiscontinuationRituximab